Ascentage Pharma Group Inc.

This Phase 3 trial is testing whether adding a new drug called lisaftoclax to a standard BTK inhibitor works better than the BTK inhibitor alone for people with CLL or SLL whose cancer has come back or not responded well to prior BTK inhibitor treatment. About 400 participants wi…

This phase 3 study tests whether adding the experimental drug olverembatinib to standard chemotherapy works better than the usual targeted therapy (a TKI) plus chemotherapy for people newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Th…

This study tests a new drug called lisaftoclax, alone or combined with other medicines, in people with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to check safety and find the best dose. About 682 adults will take part across multip…

This early-stage trial is testing an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors. The main goal is to find a safe dose and see how the body handles the drug. Participants take the pill every other day for…

This study tests a new drug called APG-2575 in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. About 75 adults will take the drug alone to see if it can shrink tumors and control the dise…

This study tests a new drug called APG-2575 in 40 people with mild-to-moderate lupus. Participants take either the drug or a placebo daily for 12 weeks. The main goal is to check safety and how the body processes the drug, not yet to see if it improves lupus symptoms.

This global phase 3 trial tests whether adding the experimental drug lisaftoclax to standard azacitidine helps older adults with newly diagnosed acute myeloid leukemia (AML) live longer. About 486 participants who cannot have intensive chemotherapy will receive either the combo o…

This study tests whether adding lisaftoclax to standard azacitidine helps people with newly diagnosed higher-risk myelodysplastic syndrome (a serious blood cancer) live longer. About 490 participants worldwide will receive either the combo or a placebo plus azacitidine. The main …

This study tests an oral drug called HQP1351 in people with chronic myeloid leukemia (CML) or a type of acute lymphoblastic leukemia (Ph+ ALL) that has not responded to at least two other treatments. The goal is to find the right dose and see how safe and effective the drug is. A…

This study is for adults with two types of blood cancer—T-PLL or NHL—that have not responded to or have returned after previous treatments. Researchers are testing a new drug called APG-115, either alone or combined with another drug APG-2575, to find the safest dose and see if i…

This early-stage study tests a new drug called APG-5918 in healthy volunteers and people with anemia (low red blood cells). The main goal is to check safety and how the body handles the drug, while also seeing if it can raise hemoglobin levels. About 105 participants will take pa…

This study looks at how the body handles a single dose of the cancer drug olverembatinib in people with normal vs. impaired liver function. Researchers will measure drug levels and safety in 48 adults. The goal is to understand if liver problems require dose adjustments.